Progesterone Receptor and Uterine Myomas Growth

Uterine myomas (leiomyomas or fibroids) are the most common benign tumors in women and have a significant impact on quality of life. The lack of highly effective non-invasive medical treatments positions a surgical technique as a prevalent therapeutic option. Recently, a new class of drugs, the selective progesterone receptor modulator (SPRM), has become available for the conservative management of myomas as a candidate of alternative medical managements. Progesterone Re ceptor and Uterine Myomas Growth.


Introduction
Uterine myomas are the most common benign tumor in women at reproductive age, with a prevalence of 70% to 80% in women by age 50 years [1][2][3][4]. Although many myomas are asymptomatic, 20% to 50% of patients develop a variety of symptoms over time, including abdominal bleeding and hypermenorrhea, subsequent anemia, pelvic pain, dysmenorrhea, infertility, and obstetric complications. The lack of highly effective non-invasive medical treatments positions a surgical technique as a common therapeutic option [5][6][7][8]. Recently, a new class of drugs, the selective progesterone receptor modulators (SPRM), has become available for the conservative management of myomas [9][10][11][12][13]. Recent excellent reports have documented the surgical and traditional non-surgical treatment options for uterine myomas [5][6][7][8]. The aim of this document is to review the known SPRM effects to understand as a potential suppressor of uterine myoma growth.

Progesterone Role in Uterine Myoma Growth
It has been discovered the critical role of progesterone pathways in the pathophysiology of uterine myomas [14][15][16].
Myoma express higher levels of both types of progesterone receptor (PR) isoforms; PR-A and PR-B [17]. Therefore, progesterone and PR play potential targets for modulating the growth of uterine myoma. SPRMs compete at the PR binding site in a tissue-specific and dose-  (a) Premenopausal patients with endometriosis, who were associated with coexistent myoma node (> 30 cm 3 ), received dienogest (2mg daily) for 6 months. The total volume of myoma declined to 59.7 % ± 5.5 %), according to Ichigo, et al. [18].
Treatment of uterine myoma with progestogens may be effective in certain cases. The early SPRM, mifepristone has been studied in randomized trials with placebo and GnRHa. Mifepristone is effective in controlling symptoms and improving patient QOL in uterine myomas [19]. Although mifepristone is used in a limited region to treat uterine myoma, any jurisdiction does not allow to use for formal indication.
In recent years, ulipristal acetate, which has been approved as an emergency contraceptive in the USA, has been the focus of clinical research [24][25][26][27][28]. Ulipristal acetate has been shown to reduce myoma volume, and induce amenorrhea in most of treated women, and is currently approved for clinical use primarily in Europe and Canada. Ulipristal acetate is a synthetic steroid derived from
Bleeding decline occurred in approximately 70% of subjects, and the intensity of menstrual bleeding decreased with each successive course of treatment. Myoma node volume also significantly decreased with each course of treatment, and this decrease was maintained through the 3-month follow-up after treatment. From a long-term safety perspective, overall adverse events were similar in rate and severity to those seen the shorter-term trials; the most common were headaches and hot flashes. The number of nodes and the age of patients do not interfere with ulipristal acetate efficacy.
To our knowledge, researchers seem to have paid little attention to coexistence of endometriosis or adenomyosis. Uterine myomas and endometriosis/adenomyosis have many common features and known to have frequent rate of coexistence of these conditions [35]. These are estrogen-dependent conditions that can often be source of pelvic pain and menstrual abnormalities. We reported successful management of a series of patients associated with endometriosis by use of a perogestine dienogest [18]. Clearly, these proposals will need additional intense clinical research on patients with adenomyosis-complicated uterine myoma who wish to avoid surgical intervention.

Conclusion
Ulipristal acetate may be a candidate for an efficient method in preoperative preparation women with symptomatic uterine myomas and is also available for safe non-surgical fertility preservation. This medical myomectomy may also support the concept of conversion of primary and secondary prevention of uterine myomas of pre-symptomatic and early symptomatic women. This area is well advanced and provides a powerful uterine myoma risk assessment tool to identify women who are either racially or genetically predisposed the development of future uterine myomas. Further studied are urgently needed to delineate the proper position of ulipristal acetate as well as other SPRMs in the anti-uterine myoma management strategies.